ASH Annual Meeting & Exposition: Leukemia

Videos

The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.

Dan Pollyea, MD, MS, on Venetoclax and IDH Mutations in Patients With AML

IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.

Dan Pollyea, MD, MS, on the Discovery and Incidence of IDH1 and IDH2 mutations in Patients With AML

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

Nicholas J. Short, MD, on the Future of ALL and Possibilities for Transplant in These Patients

Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations

Dan Pollyea, MD, Discusses Venetoclax For Patients With AML Harboring IDH Mutations

Articles

Data from initial dose cohorts of a phase 1/2 trial indicated the agent was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.

GTB-3550 TriKE Safely Drives NK Cell Function in MDS, AML

A phase 2 trial found that SY-1425 and azacitidine demonstrated clinical activity with acceptable tolerability in a heavily pretreated population of patients with relapsed/refractory acute myeloid leukemia with RARA positivity.

SY-1425, Azacitidine Combo Demonstrates Clinical Activity in Heavily Pretreated R/R AML

In preliminary findings from the ongoing first-in-human KOMET-001 trial, KO-539 showed activity in patients with relapsed or refractory acute myeloid leukemia.

KOMET-001 Trial Finds KO-539 Promotes Activity in Patients with R/R AML

An integrated analysis of 2 phase 3 studies with up to 6.5 years of follow-up reported the outcomes of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and high-risk genomic features.

Jan A. Burger, MD, PhD, on Long-Term Outcomes with Ibrutinib in High-Risk Patients with CLL/SLL

This pooled analysis from 4 clinical trials suggested that though patients with TP53 aberrations remain at risk for progression, first-line treatment with ibrutinib has meaningfully improved the poor prognosis in this high-risk population.

John N. Allan, MD, on the Impact of First-Line Ibrutinib in Patients with CLL, TP53 Aberrations

Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area.

ASH Annual Meeting & Exposition: Leukemia | Conference